MOA Life Plus Co. Ltd. (KOSDAQ:142760)
South Korea · Delayed Price · Currency is KRW 1,051.00
+55.00 (5.52%)
At close: Apr 3, 2026
MOA Life Plus Revenue
In the year 2025, MOA Life Plus had annual revenue of 11.22B KRW, down -28.24%. MOA Life Plus had revenue of 4.61B in the quarter ending December 31, 2025, with 44.32% growth.
Revenue
11.22B
Revenue Growth
-28.24%
P/S Ratio
3.82
Revenue / Employee
267.05M
Employees
42
Market Cap
42.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.22B | -4.41B | -28.24% |
| Dec 31, 2024 | 15.63B | -2.62B | -14.34% |
| Dec 31, 2023 | 18.25B | -3.76B | -17.08% |
| Dec 31, 2022 | 22.00B | -79.17B | -78.25% |
| Dec 31, 2021 | 101.17B | 20.72B | 25.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 32.97B |
| NGeneBio | 21.24B |
| ADBiotech | 12.90B |
| Eutilex.Co.,Ltd | 10.29B |
| EyeGene | 3.57B |
| SCM Lifescience | 1.54B |
| Kainos Medicine | 1.17B |
| Epibiotech | 449.62M |